Joseph P Schacht
University of Colorado, Denver · Medical University of South Carolina
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
5
all conditions, ClinicalTrials.gov
NIH grants tied to them
9
NIH RePORTER
Trial papers
14
PubMed author-name match
Trials
Studies that name Joseph P Schacht as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:43 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06575751 · Cannabidiol and Cannabis Concentrate UsersUniversity of Colorado, Denver · recruiting · Cannabis Use Disorder · principal investigator
- Ph2NCT05892432 · Clinical Trial of Rybelsus (Semaglutide) Among Adults With Alcohol Use Disorder (AUD)University of Colorado, Denver · completed · Alcohol Use Disorder · principal investigator
- Ph2NCT04066192 · Brexpiprazole in Alcohol Use DisorderUniversity of Colorado, Denver · recruiting · Alcohol Use Disorder · principal investigator
- Ph1/Ph2NCT03904849 · Cannabidiol for Alcohol Use DisorderMedical University of South Carolina · withdrawn · Alcohol Use Disorder · principal investigator
- Ph2NCT03904498 · COMT Inhibition Among Individuals With Comorbid AUD/ADHDUniversity of Colorado, Denver · completed · Alcohol Use Disorder, Attention Deficit Hyperactivity Disorder · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:44 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Cannabidiol and Cannabis Concentrate Users: A Randomized, Placebo Controlled StudyP50DA056408 · NIDA · UNIVERSITY OF COLORADO DENVER · fiscal years 2024 to 2026 · $343,528 awarded in 2026Grant number is on one of their registry trials
- Core Function IDIQ (Indefinite Delivery/Indefinite Quantity) Task Order Contracts75N94021D00 · OD · UNIVERSITY OF COLORADO DENVER · fiscal years 2021 to 2026 · $9,831 awarded in 2026Same name and institution; not confirmed by an ID
- Multi Site Randomized Trial of a GLP-1/GIP Receptor Agonist for Smoking CessationU01DA064384 · NIDA · UNIVERSITY OF SOUTHERN CALIFORNIA · fiscal years 2025 to 2026 · $2,901,274 awarded in 2026Same name and institution; not confirmed by an ID
- A pharmacogenetic human laboratory investigation of brexpiprazole in Alcohol Use DisorderR01AA027765 · NIAAA · UNIVERSITY OF COLORADO DENVER · fiscal years 2019 to 2023 · $460,245 awarded in 2023Grant number is on one of their registry trials
- An exploratory randomized controlled trial of the effects of oral semaglutide on alcohol craving and consumptionR21AA031146 · NIAAA · UNIVERSITY OF COLORADO DENVER · fiscal years 2023 · $429,000 awarded in 2023Grant number is on one of their registry trials
- COMT inhibition as a potential therapeutic target among individuals with comorbid Alcohol Use Disorder and Attention-Deficit/Hyperactivity DisorderR01AA026859 · NIAAA · UNIVERSITY OF COLORADO DENVER · fiscal years 2019 to 2023 · $330,904 awarded in 2023Grant number is on one of their registry trials
- Neural Connectivity and the Transition to Alcohol DependenceR00AA021419 · NIAAA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · fiscal years 2015 to 2017 · $248,959 awarded in 2017Same name and institution; not confirmed by an ID
- Neural Connectivity and the Transition to Alcohol DependenceK99AA021419 · NIAAA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · fiscal years 2013 to 2014 · $96,065 awarded in 2014Same name and institution; not confirmed by an ID
- A Transdisciplinary Approach to Cannabis AddictionF31DA021496 · NIDA · UNIVERSITY OF COLORADO · fiscal years 2006 to 2008 · $15,187 awarded in 2008Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 10:44 UTC. The ranking covers the 200 most relevant of 14 PubMed records, and a shared surname and initials can bring in a namesake. All 14 on PubMed
- Predictors of Naltrexone Response in a Randomized Trial: Reward-Related Brain Activation, OPRM1 Genotype, and Smoking Status.Neuropsychopharmacology · 201791 citationsRCR 4.7
- Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues.Neuropsychopharmacology · 201374 citationsRCR 3.1
- Varenicline effects on drinking, craving and neural reward processing among non-treatment-seeking alcohol-dependent individuals.Psychopharmacology (Berl) · 201450 citationsRCR 2.1
- Effects of a GABA-ergic medication combination and initial alcohol withdrawal severity on cue-elicited brain activation among treatment-seeking alcoholics.Psychopharmacology (Berl) · 201329 citationsRCR 1.1
- Nicotine-Use/Smoking Is Associated with the Efficacy of Naltrexone in the Treatment of Alcohol Dependence.Alcohol Clin Exp Res · 201824 citationsRCR 1.5
- Dopaminergic Genetic Variation Influences Aripiprazole Effects on Alcohol Self-Administration and the Neural Response to Alcohol Cues in a Randomized Trial.Neuropsychopharmacology · 201821 citationsRCR 1.2
- Aripiprazole Suppression of Drinking in a Clinical Laboratory Paradigm: Influence of Impulsivity and Self-Control.Alcohol Clin Exp Res · 201719 citationsRCR 1.0
- Effects of pharmacological and genetic regulation of COMT activity in alcohol use disorder: a randomized, placebo-controlled trial of tolcapone.Neuropsychopharmacology · 202218 citationsRCR 1.9
- Neurocognitive performance, alcohol withdrawal, and effects of a combination of flumazenil and gabapentin in alcohol dependence.Alcohol Clin Exp Res · 201113 citationsRCR 0.5
- Epigenetic moderators of naltrexone efficacy in reducing heavy drinking in Alcohol Use Disorder: a randomized trial.Pharmacogenomics J · 20228 citationsRCR 0.9